Types of Research
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
Cash transfer programs are interventions that directly provide cash to target specific populations with the aim of reducing poverty and supporting a variety of development outcomes. Low- and middle-income countries have increasingly adopted cash transfer programs as central elements of their poverty reduction and social protection strategies. Bastagli et al. (2016) report that around 130 low- and middle-income countries have at least one UCT program, and 63 countries have at least one CCT program (up from 27 countries in 2008). Through a comprehensive review of literature, this report primarily considers the evidence of the long-term impacts of cash transfer programs in low- and lower middle-income countries. A review of 54 reviews that aggregate and summarize findings from multiple studies of cash transfer programs reveals largely positive evidence on long-term outcomes related to general health, reproductive health, nutrition, labor markets, poverty, and gender and intra-household dynamics, though findings vary by context and in many cases overall conclusions on the long-term impacts of cash transfers are mixed. In addition, evidence on long-term impacts for many outcome measures is limited, and few studies explicitly aim to measure long-term impacts distinctly from immediate or short-term impacts of cash transfers.
The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.
On July 10, 2009 at the Italy G8 summit, attendees issued a joint statement pledging to contribute $20 billion towards agricultural development and food security in the developing world over the next three years. This research brief notes the status of the contributions made to the L’Aquila Food Security Initiative and whether any of the $20 billion will be allocated to agricultural research. We conclude that no declarations have been made as of September 2009 on how much of the $20 billion will be allocated to agricultural research, and which types of research will be funded by the initiative.
This brief presents an in depth analysis of the FAO’s methodology behind their calculations for hunger. The analysis includes a review of the key assumptions made by the FAO in their calculations, critiques of their methodology, and recommendations for future research. The critiques include opinions from the literature on the subject as well as from the authors of the request.
This brief presents an initial examination of the possibility of using Disability Adjusted Life Years (DALYs) as a way to evaluate agricultural interventions. We review DALYs, their formulation, and the data necessary to compute values. A review of relevant literature suggests that to use DALYs as an evaluative tool, an agricultural intervention must be tied to a specific disease, and from there, impacts on DALYs can be assessed.